Dyne Therapeutics, Inc.
DYN Nasdaq· Pharmaceutical Preparations
Last close · Oct 27, 2026
$16.94
KIRA · Stoqly’s AI analyst, in plain words
- Dyne Therapeutics, Inc. lost $446M in fiscal 2025.
- Free cash flow was −$405M in fiscal 2025, — of revenue.
- Dyne Therapeutics, Inc. has $962M more cash than debt.
Market cap
$2.8B
P/E
—
Revenue
—
Net income
−$446M
Free cash flow
−$405M
Operating margin
—
Dyne Therapeutics, Inc. in 30 seconds · fiscal 2025
Does it make a profit?
−$446M
No. It lost money last year.
How healthy are the accounts?
3 / 7
Weak. It passes 3 of 7 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Dyne Therapeutics, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 2, 2026
- Legal name
- Dyne Therapeutics, Inc.
- CIK
- 0001818794
Dyne Therapeutics, Inc. · DYN
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Net income | −$149M | −$168M | −$236M | −$317M | −$446M |
| Diluted EPS | −$2.93 | −$3.23 | −$3.95 | −$3.37 | −$3.47 |
| Cash | |||||
| Cash from operations | −$120M | −$154M | −$188M | −$292M | −$403M |
| Capital expenditure | $3.6M | $3.1M | $0.7M | $2.4M | $1.9M |
| Free cash flow | −$123M | −$157M | −$189M | −$295M | −$405M |
| Share count change | 253.5% | 2.1% | 14.8% | 57.7% | 36.4% |
| Debt and strength | |||||
| Cash and short-term investments | $377M | $256M | $123M | $642M | $1.1B |
| Debt incl. finance leases | — | — | — | $0.0M | $149M |
| Shareholders' equity | $368M | $252M | $91.3M | $630M | $972M |
| Current ratio | 13.3x | 9.5x | 2.5x | 15.6x | 22.3x |
| Returns and quality | |||||
| Return on capital | — | — | — | — | −3,526.6% |
| Return on equity | −42.0% | −54.2% | −137.3% | −88.0% | −55.7% |
| Return on tangible equity | −40.5% | −66.6% | −258.4% | −50.4% | −45.9% |
| Piotroski F-score | — | — | — | — | 3 |
| Altman Z'' | 8.1 | 2.0 | −17.9 | 8.8 | 4.2 |
Insiders bought, 12 months
$0.3M
1 insider
Insiders sold, 12 months
$169M
6 insiders
Of sales under plans
100%
$169M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Dyne Therapeutics, Inc. · DYN
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $16.94 a share, the company is worth $2.8B.
Source: SEC EDGAR XBRL filings (CIK 0001818794). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.